In particular, one study reported that increased plasma concentrations of FL after chemotherapy induces resistance to FLT3 inhibitors—including midostaurin, quizartinib, sorafenib, and lestaurtinib—in AML cells with FLT3wt or mutant FLT3 (FLT3mut) [21]. The gene discussed is FLT3; the disease is acute myeloid leukemia.